CONMED (CNMD) Q2 2024 earnings summary

Executive summary

• Q2 2024 sales reached $332.1 million, up 4.5% year-over-year (5.2% in constant currency), marking a record high for quarterly sales.

• GAAP net income for Q2 was $30.0 million, more than doubling from $13.7 million in Q2 2023, with diluted EPS at $0.96–$0.97; adjusted EPS was $0.98, up 18.1%.

• Gross profit margin improved to 55.3% from 53.7% year-over-year, reflecting favorable product mix and lower costs.

• Management highlighted ongoing supply chain constraints, especially in orthopedics, leading to lost sales and a downward revision of full-year guidance.

• General Surgery segment, particularly AirSeal, showed robust demand and growth, offsetting orthopedic declines.

Financial highlights

• U.S. sales grew 6.1% and international sales 2.6% as reported (4.0% in constant currency) in Q2.

• General Surgery revenue increased 8.9%–9.4% globally, while Orthopedic Surgery declined 0.1%–0.9%.

• Single-use products accounted for 84% of Q2 revenue, growing 5.5%–6.2% year-over-year in constant currency.

• Adjusted gross margin improved by 90 basis points to 55.3% in Q2.

• Operating income margin rose to 14.2% from 8.6% in Q2 2023.

Outlook and guidance

• Full-year 2024 revenue guidance set at $1.305–$1.315 billion, reflecting 5%–6% constant currency growth, revised down from prior $1.330–$1.355 billion.

• Adjusted EPS guidance for 2024 is $3.95–$4.02, representing 14.5%–16.5% growth, down from $4.25–$4.35.

• Gross margin projected to reach 57% by Q4, with sequential improvement expected.

• Foreign currency expected to be a $5M–$10M revenue headwind in 2024.

• Q3 expected at the lower end of growth range due to orthopedic supply issues; Q4 expected to improve.